Les nouveaux inhibiteurs de la pompe à protons, un progrès dans la prise en charge des maladies acido-peptiques ?

[1]  Hirokazu Takahashi,et al.  Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: Which is suitable for on‐demand therapy? , 2003, Journal of Gastroenterology and Hepatology.

[2]  S. Edwards,et al.  A review of the clinical and economic impact of using esomeprazole or lansoprazole for the treatment of erosive esophagitis. , 2003, Clinical therapeutics.

[3]  R. Löfberg.  Medical treatment of mild to moderately active Crohn's disease , 2003 .

[4]  A. Blum,et al.  Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors , 2003, Alimentary pharmacology & therapeutics.

[5]  J. Pisegna,et al.  Rabeprazole is superior to omeprazole for the inhibition of peptone meal‐stimulated gastric acid secretion in Helicobacter pylori‐negative subjects , 2003, Alimentary pharmacology & therapeutics.

[6]  M. Postma,et al.  Meta‐analysis: comparing the efficacy of proton pump inhibitors in short‐term use , 2003, Alimentary pharmacology & therapeutics.

[7]  A. Blum,et al.  Fast and complete control of heartburn in on-demand rabeprazole (RAB) maintenance therapy in patients with nonerosive reflux disease (NERD) , 2003 .

[8]  A. Blum,et al.  On-demand rabeprazole therapy provides heartburn control in long-term management of nonerosive reflux disease (NERD) , 2003 .

[9]  J. Hatlebakk.  Review article: gastric acidity − comparison of esomeprazole with other proton pump inhibitors , 2003, Alimentary pharmacology & therapeutics.

[10]  J. Devière,et al.  Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results , 2003, Alimentary pharmacology & therapeutics.

[11]  D. Johnson.  Review of esomeprazole in the treatment of acid disorders , 2003, Expert opinion on pharmacotherapy.

[12]  B. Thjódleifsson,et al.  A randomized, double‐blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro‐oesophageal reflux disease over 5 years , 2003, Alimentary pharmacology & therapeutics.

[13]  F. Pace,et al.  On-demand proton pump inhibitor therapy in patients with gastro-oesophageal reflux disease. , 2002, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[14]  K. Ogawa,et al.  Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers , 2002, Alimentary pharmacology & therapeutics.

[15]  M. Whitaker.  Proton pump inhibitors in the elderly population. , 2002, European journal of gastroenterology & hepatology.

[16]  K. Baisley,et al.  Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24‐h intragastric pH and serum gastrin in healthy subjects , 2002, Alimentary pharmacology & therapeutics.

[17]  W. Orr,et al.  Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial , 2002, American Journal of Gastroenterology.

[18]  S. Dodd,et al.  Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs. , 2002, Managed care.

[19]  R. Hegedus,et al.  Onset of symptom relief with rabeprazole: a community‐based, open‐label assessment of patients with erosive oesophagitis , 2002, Alimentary pharmacology & therapeutics.

[20]  A. Blum,et al.  A randomized, double‐blind, comparative study of standard‐dose rabeprazole and high‐dose omeprazole in gastro‐oesophageal reflux disease , 2002, Alimentary pharmacology & therapeutics.

[21]  D. Johnson,et al.  Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis , 2002, American Journal of Gastroenterology.

[22]  B. Thjódleifsson.  Treatment of Acid-Related Diseases in the Elderly with Emphasis on the Use of Proton Pump Inhibitors , 2002, Drugs & aging.

[23]  T. Andersson,et al.  Pharmacokinetics and pharmacodynamics of esomeprazole, the S‐isomer of omeprazole , 2001, Alimentary pharmacology & therapeutics.

[24]  M. Robinson.  New-generation proton pump inhibitors: overcoming the limitations of early-generation agents. , 2001, European journal of gastroenterology & hepatology.

[25]  G. Sachs.  Improving on PPI-based therapy of GORD. , 2001, European journal of gastroenterology & hepatology.

[26]  N. Talley,et al.  Esomeprazole 20 mg maintains symptom control in endoscopy‐negative gastro‐oesophageal reflux disease: a controlled trial of ‘on‐demand’ therapy for 6 months , 2001, Alimentary pharmacology & therapeutics.

[27]  P. Kahrilas,et al.  Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial , 2001, American Journal of Gastroenterology.

[28]  T. Andersson,et al.  Drug Interaction Studies with Esomeprazole, the (S)-Isomer of Omeprazole , 2001, Clinical pharmacokinetics.

[29]  K. Röhss,et al.  Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro‐oesophageal reflux disease , 2000, Alimentary pharmacology & therapeutics.

[30]  C. Wilder-Smith,et al.  Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg , 2000 .

[31]  T. Ishizaki,et al.  Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole , 1999, Alimentary pharmacology & therapeutics.

[32]  T. Humphries,et al.  Review article: drug interactions with agents used to treat acid‐related diseases , 1999, Alimentary pharmacology & therapeutics.

[33]  K. Ohashi,et al.  CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans , 1999 .

[34]  Williams,et al.  A placebo‐controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24‐h intragastric acidity and plasma gastrin concentrations in young healthy male subjects , 1998, Alimentary pharmacology & therapeutics.

[35]  T. Humphries,et al.  Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro‐oesophageal reflux disease , 1997, Alimentary pharmacology & therapeutics.

[36]  G. Sachs,et al.  Sites of Reaction of the Gastric H,K-ATPase with Extracytoplasmic Thiol Reagents* , 1997, The Journal of Biological Chemistry.